Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2016 02:35 ET | Source: Active Biotech

Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

LUND, Sweden and TEL AVIV, Israel, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Active Biotech AB (NASDAQ OMX NORDIC: ACTI) and NeoTX Therapeutics Ltd. announced today that they have entered into a licensing...
October 26, 2016 02:30 ET | Source: Active Biotech

Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund (Sweden) and Tel Aviv (Israel),...
October 26, 2016 02:30 ET | Source: Active Biotech

Active Biotech och NeoTX ingår partnerskap för utveckling och kommersialisering av ANYARA för immunonkologi

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund och Tel Aviv (Israel), 26...
October 26, 2016 02:27 ET | Source: Active Biotech

Active Biotech postpone publication of the interim report

LUND, Sweden, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Active Biotech has decided to postpone the publication of the interim report for January-September 2016 to November 11, 2016, after stock markets...
October 26, 2016 02:25 ET | Source: Active Biotech

Active Biotech senarelägger offentliggörande av delårsrapport

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotech har beslutat att...
October 26, 2016 02:25 ET | Source: Active Biotech

Active Biotech postpone publication of the interim report

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotech has decided to...
September 19, 2016 02:44 ET | Source: Active Biotech

Active Biotech update on laquinimod Development: The U.S, Food and Drug administration rescinds the Special Protocol Assessment for laquinimod

LUND, Sweden, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Active Biotech (Nasdaq Stockholm: ACTI) provided an update today on laquinimod which is being developed in multiple sclerosis (MS) and Huntington's...
September 19, 2016 02:30 ET | Source: Active Biotech

Active Biotech update on laquinimod Development: The U.S, Food and Drug administration rescinds the Special Protocol Assessment for laquinimod

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, September 19, 2016 - Active...
September 19, 2016 02:30 ET | Source: Active Biotech

Active Biotech uppdaterar om utvecklingen av laquinimod: Special Protocol Assessment (SPA) för laquinimod upphävs efter diskussion med FDA

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 19 september 2016 - Active...
August 11, 2016 02:35 ET | Source: Active Biotech

Active Biotech AB Interim report January - June 2016

LUND, Sweden, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from both the pivotal...